Close Menu

Hitting the Big-Time

FDA has approved Novartis' Ilaris to treat a rare, genetic autoinflammatory disease, reports the Wall Street Journal. The paper's Health Blog adds that Ilaris is an example of that prized goal, personalized medicine. "It's also the first concrete result of Novartis's seven-year effort to target the genetic causes of disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.